Evidence map›Paper›PMID 39300608›Full record

ArticleBritish journal of pharmacology2024

Selective modulation of epileptic tissue by an adenosine A

Anwesha Ghosh, Leonor Ribeiro-Rodrigues, Gabriele Ruffolo, Veronica Alfano, Cátia Domingos, Nádia Rei, Dilip K Tosh, Diogo M Rombo, Tatiana P Morais, Cláudia A Valente and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Anwesha GhoshInstituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Leonor Ribeiro-RodriguesInstituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Gabriele RuffoloDepartment of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.
Veronica AlfanoIRCCS San Raffaele Roma, Rome, Italy.
Cátia DomingosInstituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Nádia ReiInstituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Dilip K ToshMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Diogo M RomboInstituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Tatiana P MoraisNeuroscience Division, School of Bioscience, Cardiff University, Cardiff, UK.
Cláudia A ValenteInstituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Sara XapelliInstituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Beatriz BordadáguaHeidelberg Institute for Theoretical Studies (HITS), Heidelberg, Germany.
Alexandre Rainha-CamposCentro de Referência para a área da Epilepsia Refratária (ERN EpiCARE Member), CHULN, Lisbon, Portugal.
Carla BentesCentro de Referência para a área da Epilepsia Refratária (ERN EpiCARE Member), CHULN, Lisbon, Portugal.
Eleonora AronicaAmsterdam Neuroscience, Department of (Neuro)Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Maria José DiógenesInstituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Sandra H VazInstituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Joaquim A RibeiroInstituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Eleonora PalmaDepartment of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.
Kenneth A JacobsonMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-8104-1493
Ana M SebastiãoInstituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.

Funding

Development Of Drugs Acting At Adenosine ReceptorsZIADK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$10.4M
Drugs that Act at Adenosine ReceptorsZ01DK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 1991 to 2008
$854k
Fundação para a Ciência e a Tecnologia PD/BD/150344/2019Fundação para a Ciência e a Tecnologia PTDC/MED-FAR/30933/2017Fundação para a Ciência e a Tecnologia PTDC/MED-FAR/4834/2021H2020-WIDESPREAD-05-2017-Twinning (EpiEpiNet) 952455Instituto de Medicina Molecular João Lobo Antunes iMM-BI-4-2022International Society for NeurochemistryIntramural NIH HHS Z01 DK031117Intramural NIH HHS Z99 DK999999Intramural NIH HHS ZIA DK031117Italian Ministry of HealthItalian Ministry of University and Research PRIN 2022Italian Ministry of University and Research PRIN-PNRR 2022NIDDK Intramural Research Program ZIADK031117Sapienza Università di Roma RG12117A8697DCF1Sapienza Università di Roma RM11916B84D24429
6 · The paper itself

Abstract

background and purposeAdenosine, through the A EXPERIMENTAL APPROACH: Excitatory synaptic currents, field potentials, spontaneous activity, [ KEY

resultsMRS5474 (50-500 nM) was devoid of effect upon rodent excitatory synaptic signals in hippocampal slices, except when hyperexcitability was previously induced in vivo or ex vivo. MRS5474 inhibited GABA transporter type 1 (GAT-1)-mediated γ-aminobutyric acid (GABA) uptake, an action not blocked by an A CONCLUSION AND IMPLICATIONS: We identified a drug that activates A

Indexed as

Adenosine A3 Receptor AgonistsAnticonvulsantsEpilepsyHippocampusReceptor, Adenosine A3AdenosineAnimalsExcitatory Postsynaptic PotentialsFemaleGABA Plasma Membrane Transport Proteinsgamma-Aminobutyric AcidHumansMaleMiceRatsRats, Sprague-DawleyAdenosineAdenosine A3 Receptor AgonistsAnticonvulsantsGABA Plasma Membrane Transport Proteinsgamma-Aminobutyric AcidReceptor, Adenosine A3adenosine A1 receptoradenosine A3 receptorepilepsyGABAergic transmissionhippocampusneuronal excitability

Identifiers

PMID39300608
PMCPMC11578780

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.